Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP23573 in recurrent/persistent endometrial cancer
NCT00122343Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Primary completion
- Jan 2008
- Modality
- Classical Binding Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ridaforolimus in endometrial cancer (EC), sponsored by Merck & Co. Primary endpoint: Efficacy of AP23573. Started Aug 2005; status: completed.
02
Drugs
ridaforolimus
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00122343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122343.